RGC Resources, Inc. Declares Quarterly Dividend ROANOKE, Va., May 02, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (NASDAQ: RGCO), at its meeting on May 1, 2024, declared a quarterly dividend of $0.20 per share on the Company’s common stock. The dividend will be paid on August 1, 2024 to shareholders of record on July 17, 2024. This is the Company’s 321st consecutive quarterly cash dividend. RGC Resources, Inc. provides energy and related products and services to customers in Virginia through its operating subsidiaries including Roanoke Gas Company and RGC Mid...
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024 CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company’s first quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Lif...
RGC Resources, Inc. Reports Second Quarter Earnings ROANOKE, Va., May 01, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) announced consolidated Company earnings of $6,443,390, or $0.63 per share, for the second quarter ended March 31, 2024, compared to $6,341,886, or $0.64 per share, for the fiscal quarter ended March 31, 2023. The increase over the quarter a year ago included $1.2 million in earnings from the Company’s investment in the Mountain Valley Pipeline, LLC (“MVP”), as well as improved utility margins which inflationary cost increases largely offset. Continued in...
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the approval of its first clinical trial application (CTA) for its RestorAATion-2 clinical trial of WVE-006...
RGC Resources, Inc. Schedules Second Quarter 2024 Earnings Call ROANOKE, Va., April 25, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal second quarter 2024 on Monday, May 6, 2024 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at . Interested parties may access the conference call by dialing toll-free 1-877-304-9269 and entering conference identification number 917621. An archi...
TELA Bio to Announce First Quarter 2024 Financial Results MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
SeaChange Announces an Agreement to be Acquired by Enghouse and Termination of Previously Announced Proposed Acquisition by Partner One BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- . (OTC: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging Free Ad-Supported Streaming TV services (FAST) development, has entered into an asset purchase agreement (the “Enghouse Purchase Agreement”) under which an affiliate of Enghouse Systems Limited (“Enghouse”), a leading global telecommunication technology and solutions company that prov...
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation GalNAc-siRNA format with potential for best-in-class potency and durability GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas Wave is on track to initiate a clinical trial of its wholly owned INHBE pro...
SeaChange Announces a Second Amendment to Purchase Agreement with Partner One Along with Further Increased Purchase Price BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- . (OTC: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging Free Ad-Supported Streaming TV services (FAST) development, has entered into a second omnibus amendment (such amendment, “Amendment No. 2”) to the asset purchase agreement and software purchase agreement (the “Original Purchase Agreements”) previously announced on March 11, 2024, as amended by the ...
Moody's Ratings assigned a Ba3 rating (also on review for upgrade) to Sunoco LP's (Sunoco) proposed $1.5 billion senior unsecured notes and placed the notes on review for upgrade. The notes will be issued in two tranches, due in 2029 and 2032. All other ratings of Sunoco are unchanged, including its...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and roboti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.